Diagnostics Group Refutes FDA’s Concerns

The Association for Molecular Pathology finds fault in the agency’s report on safety issues associated with certain lab tests.

kerry grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PUBLIC DOMAIN IMAGES, AMANDA MILLS, USCDCPA group representing the interests of the molecular diagnostics field laid out its troubles this week (December 13) with the US Food and Drug Administration’s (FDA) concerns over laboratory developed tests. In its report, the Association for Molecular Pathology (AMP) contends that the FDA’s review of 20 tests “makes dubious claims, fails to provide significant context for the information provided, and relies on articles from the lay news media to assert its scientific positions.”

In November, the FDA had released its evaluation of the tests, which included ovarian cancer screens, Lyme disease tests, and assays to detect fetal chromosomal abnormalities. The agency found evidence of false positives, false negatives, and “information with no proven relevance to the disease or condition for which they are intended for use.”

The FDA is planning to wield greater regulatory scrutiny over such tests. But AMP concluded “only a few of the 20 tests identified by the FDA could cause patient harms that FDA oversight might have prevented.”

GenomeWeb reported that the association “also concluded many of the 20 examples in the FDA’s report are the result of physicians using treatments outside of established medical practice or failing to follow up a screening test ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • kerry grens

    Kerry Grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide